ZA200809356B - Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith - Google Patents

Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith

Info

Publication number
ZA200809356B
ZA200809356B ZA2008/09356A ZA200809356A ZA200809356B ZA 200809356 B ZA200809356 B ZA 200809356B ZA 2008/09356 A ZA2008/09356 A ZA 2008/09356A ZA 200809356 A ZA200809356 A ZA 200809356A ZA 200809356 B ZA200809356 B ZA 200809356B
Authority
ZA
South Africa
Prior art keywords
compositions
methods
treatment therewith
haloaryl substituted
aminopurines
Prior art date
Application number
ZA2008/09356A
Other languages
English (en)
Inventor
Ronald Albers
Leticia Ayala
Steven S Clareen
Mederos Maria M Delgado
Robert Hilgraf
Sayee G Hegde
Kevin Hughes
Adam Kois
Veronique Plantevin-Krenitsky
Meg Mccarrick
Lisa Nadolny
Moorthy S S Palanki
Kiran Sahasramudhe
John Sapienza
Yoshitaka Satoh
Marianne K Sloss
Elise Sudbeck
Jonathan Wright
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Publication of ZA200809356B publication Critical patent/ZA200809356B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2008/09356A 2006-04-26 2008-10-31 Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith ZA200809356B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/411,413 US7521446B2 (en) 2005-01-13 2006-04-26 Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
PCT/US2007/010258 WO2007127382A1 (en) 2006-04-26 2007-04-25 Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith

Publications (1)

Publication Number Publication Date
ZA200809356B true ZA200809356B (en) 2010-02-24

Family

ID=38462340

Family Applications (3)

Application Number Title Priority Date Filing Date
ZA2008/09356A ZA200809356B (en) 2006-04-26 2008-10-31 Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
ZA2009/07418A ZA200907418B (en) 2006-04-26 2009-10-22 Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
ZA2011/03036A ZA201103036B (en) 2006-04-26 2011-04-20 Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith

Family Applications After (2)

Application Number Title Priority Date Filing Date
ZA2009/07418A ZA200907418B (en) 2006-04-26 2009-10-22 Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
ZA2011/03036A ZA201103036B (en) 2006-04-26 2011-04-20 Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith

Country Status (14)

Country Link
US (2) US7521446B2 (OSRAM)
EP (1) EP2010186B1 (OSRAM)
JP (1) JP2009535346A (OSRAM)
KR (1) KR20090013804A (OSRAM)
CN (2) CN103351389B (OSRAM)
AU (1) AU2007243287B2 (OSRAM)
BR (1) BRPI0710805A2 (OSRAM)
CA (1) CA2684999C (OSRAM)
ES (1) ES2400257T3 (OSRAM)
IL (1) IL194865A (OSRAM)
MX (1) MX2008013616A (OSRAM)
NZ (1) NZ572467A (OSRAM)
WO (1) WO2007127382A1 (OSRAM)
ZA (3) ZA200809356B (OSRAM)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7256196B1 (en) * 2003-12-09 2007-08-14 The Procter & Gamble Company Purine cytokine inhibitors
US7759342B2 (en) * 2005-01-13 2010-07-20 Signal Pharmaceuticals, Llc Methods of treatment and prevention using haloaryl substituted aminopurines
US7521446B2 (en) * 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7723340B2 (en) * 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
NZ572381A (en) * 2006-04-28 2011-01-28 Shionogi & Co Amine derivative having npy y5 receptor antagonist activity
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
ES2567051T3 (es) * 2006-10-27 2016-04-19 Signal Pharmaceuticals, Llc Formas sólidas que comprenden 4-[9-(3S)-(tetrahidro-furan-3-il)-8-(2,4,6-trifluoro-fenilamino)-9H-purin-2-ilamino]-trans-ciclohexan-1-ol, sus composiciones y sus usos
WO2008112311A1 (en) 2007-03-14 2008-09-18 Washington University Methods for identifying diabetes and obesity therapeutics
SA08290668B1 (ar) 2007-10-25 2012-02-12 شيونوجي آند كو.، ليمتد مشتقات أمين لها نشاط مضاد لمستقبل npy y5 واستخداماتها
WO2009078999A1 (en) 2007-12-17 2009-06-25 Janssen Pharmaceutica N.V. Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1
WO2009079000A1 (en) * 2007-12-17 2009-06-25 Janssen Pharmaceutica N.V. Imidazolopyrimidine modulators of trpv1
BRPI0917791B1 (pt) 2008-08-22 2022-03-22 Novartis Ag Compostos de pirrolopirimidina como inibidores de cdk, bem como composição farmacêutica e combinação
UY32138A (es) * 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
UY32470A (es) * 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
US8227618B2 (en) * 2009-04-23 2012-07-24 Shionogi & Co., Ltd. Amine-derivatives having NPY Y5 receptor antagonistic activity and the uses thereof
US20130034495A1 (en) * 2009-12-09 2013-02-07 Marie Georges Beauchamps Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol
US9138309B2 (en) 2010-02-05 2015-09-22 Allergan, Inc. Porous materials, methods of making and uses
US9205577B2 (en) * 2010-02-05 2015-12-08 Allergan, Inc. Porogen compositions, methods of making and uses
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
US11202853B2 (en) * 2010-05-11 2021-12-21 Allergan, Inc. Porogen compositions, methods of making and uses
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
US8759537B2 (en) 2010-08-20 2014-06-24 Boehringer Ingelheim International Gmbh 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
US8680076B2 (en) 2010-10-25 2014-03-25 Signal Pharmaceuticals, Llc Methods of treatment, improvement and prevention using haloaryl substituted aminopurines
US8603527B2 (en) 2010-10-25 2013-12-10 Signal Pharmaceuticals, Llc Pharmaceutical formulations of a substituted diaminopurine
US8466186B2 (en) 2010-12-10 2013-06-18 Boehringer Ingelheim International Gmbh Compounds
US8486968B2 (en) 2010-12-10 2013-07-16 Boehringer Ingelheim International Gmbh Compounds
US8674113B2 (en) 2010-12-10 2014-03-18 Boehringer Ingelheim International Gmbh Compounds
US20140213553A1 (en) 2011-05-03 2014-07-31 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
US9493464B2 (en) 2012-02-29 2016-11-15 The Scripps Research Institute Wee1 degradation inhibitors
CN105144689B (zh) * 2013-04-26 2018-04-13 富士胶片株式会社 摄像装置及图像显示方法
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
HUE054694T2 (hu) * 2014-10-06 2021-09-28 Signal Pharm Llc Szubsztituált aminpurin vegyületek, ezek összetételei, és az ezekkel végzett kezelések módszerei
CN109819649B (zh) 2016-04-01 2023-02-28 西格诺药品有限公司 氨基嘌呤化合物的固体形式及其使用方法
SG10202009589UA (en) 2016-04-01 2020-10-29 Signal Pharm Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
WO2017210399A1 (en) 2016-06-02 2017-12-07 Celgene Corporation Animal and human anti-malarial agents
AR108665A1 (es) 2016-06-02 2018-09-12 Celgene Corp Derivados de aminopurina como agentes anti-tripanosómicos y anti-leishmania
CN106265673B (zh) * 2016-09-18 2019-09-20 中国农业大学 一种化合物的应用
WO2019070827A1 (en) 2017-10-04 2019-04-11 Celgene Corporation PROCESSES FOR THE PREPARATION OF CIS-4 [2 - {(3S, 4R) -3-FLUOROOXAN-4-YL] AMINO) -8- (2,4,6-TRICHLOROANILINO) -9H-PURIN-9-YL] -1 -MÉTHYLCYCLOHEXANE-1-carboxamide
CA3078368A1 (en) 2017-10-04 2019-04-11 Celgene Corporation Compositions and methods of use of cis-4-[2-{[(3s,4r)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9h-purin-9-yl]-1-methylcyclohexane-1-carboxamide
CN109384788B (zh) * 2018-10-16 2021-05-14 成都大学 嘌呤系列衍生物及其制备方法和用途
CN111544657B (zh) * 2020-05-11 2022-01-11 北京大学第三医院（北京大学第三临床医学院） 一种具有良好可打印性的细胞3d打印生物墨水制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5332744A (en) * 1989-05-30 1994-07-26 Merck & Co., Inc. Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
JP2001516694A (ja) * 1997-08-07 2001-10-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア プロテインキナーゼ、ｇプロテイン及びポリメラーゼのプリン阻害剤
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
CN1919859A (zh) 1999-11-12 2007-02-28 法玛赛特有限公司 2＇－脱氧－l－核苷的合成
WO2001049688A1 (en) 2000-01-07 2001-07-12 Universitaire Instelling Antwerpen Purine derivatives, process for their preparation and use thereof
AU2001295026B2 (en) 2000-09-06 2008-04-03 Novartis Vaccines And Diagnostics, Inc. Inhibitors of glycogen synthase kinase 3
PL211125B1 (pl) 2000-09-11 2012-04-30 Novartis Vaccines & Diagnostic Pochodne chinolinonu jako inhibitory kinazy tyrozynowej, kompozycje je zawierające i ich zastosowanie
EP1381594A1 (en) 2001-04-13 2004-01-21 Boehringer Ingelheim Pharmaceuticals Inc. Urea compounds useful as anti-inflammatory agents
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
US7256196B1 (en) * 2003-12-09 2007-08-14 The Procter & Gamble Company Purine cytokine inhibitors
AU2005298637B8 (en) 2004-10-29 2012-12-06 Janssen Sciences Ireland Uc HIV inhibiting bicyclic pyrimidine derivatives
US7723340B2 (en) * 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7759342B2 (en) * 2005-01-13 2010-07-20 Signal Pharmaceuticals, Llc Methods of treatment and prevention using haloaryl substituted aminopurines
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
ES2567051T3 (es) 2006-10-27 2016-04-19 Signal Pharmaceuticals, Llc Formas sólidas que comprenden 4-[9-(3S)-(tetrahidro-furan-3-il)-8-(2,4,6-trifluoro-fenilamino)-9H-purin-2-ilamino]-trans-ciclohexan-1-ol, sus composiciones y sus usos

Also Published As

Publication number Publication date
ES2400257T3 (es) 2013-04-08
WO2007127382A1 (en) 2007-11-08
CN103351389B (zh) 2015-10-28
CA2684999A1 (en) 2007-11-08
CN103351389A (zh) 2013-10-16
BRPI0710805A2 (pt) 2011-08-16
US20070060598A1 (en) 2007-03-15
US20090275564A1 (en) 2009-11-05
IL194865A (en) 2015-08-31
AU2007243287A1 (en) 2007-11-08
MX2008013616A (es) 2009-03-06
EP2010186A1 (en) 2009-01-07
ZA201103036B (en) 2012-08-29
JP2009535346A (ja) 2009-10-01
IL194865A0 (en) 2009-08-03
ZA200907418B (en) 2011-12-28
EP2010186B1 (en) 2012-12-26
CA2684999C (en) 2013-11-26
NZ572467A (en) 2010-10-29
AU2007243287B2 (en) 2012-02-16
CN101478972A (zh) 2009-07-08
US8101588B2 (en) 2012-01-24
KR20090013804A (ko) 2009-02-05
US7521446B2 (en) 2009-04-21

Similar Documents

Publication Publication Date Title
IL194865A0 (en) Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
IL193297A0 (en) Imidazole-based compounds, compositions comprising them and methods of their use
GB0700919D0 (en) Degradable compositions, apparatus comprising same, and methods of use
BRPI0814941A2 (pt) Composição de tratamentode semente, e, método de tratamento de semente.
IL233634A0 (en) Methods, compositions and kits for treating medical conditions
SI2963031T1 (sl) Predzdravila tetrahidrokanabinola, sestavki, ki obsegajo predzdravila tetrahidrokanabinola in postopki njihove uporabe
IL209188A (en) Sweetener, preparations containing it and methods of manufacture
SI2079760T1 (sl) Sestavki in metode za zdravljenje okužb
IL197148A0 (en) Methods and compositions for the treatment of antibody mediated neuropathies
GB0718446D0 (en) Compositions and methods for the treatment of infection
AU2007243282A8 (en) Compositions and methods for the treatment of cardiovascular disease
EP2340297A4 (en) COMPOSITION, ITS MANUFACTURING METHOD AND USE
IL208613A (en) Aztidine derivatives, methods of preparation, preparations containing them and their use
IL200387A0 (en) Heterocylic compounds, compositions comprising them and methods of their use
ZA200902255B (en) Synthesis, methods of using, and compositions of cycloalkylmethylamines
WO2008027600A3 (en) Imatinib compositions
ZA201000992B (en) Anti-viral compounds, compositions, and methods of use
GB0601143D0 (en) Uses, methods and compositions
EP2074258A4 (en) FIBER PLATES, THEIR MANUFACTURE AND USE
ZA200706662B (en) Haloaryl substituted Aminopurines, compositions thereof, and methods of treatment therewith
EP2124968A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUSCLE ATROPHY
EP2008289A4 (en) CIRCUIT AND MANUFACTURING METHOD AND USE
GB0601950D0 (en) Compositions and methods of treating diabetes
GB0504657D0 (en) Compositions and methods of treatment
GB0808326D0 (en) Compositions and methods for the treatment of fybromyalgia